Brief: Canbridge Pharmaceuticals Got Approval To Treat Patients With PNH In Phase 1B/2 Trial
07/02/2022 15:14
Feb 7 (Reuters) - Canbridge Pharmaceuticals Inc 1228.HK :
* CANBRIDGE PHARMACEUTICALS GOT APPROVAL TO TREAT PATIENTS
WITH
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PHASE 1B/2 TRIAL IN
CHINA
Source text for Eikon: ID:nHKScg5vkP
Further company coverage: 1228.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares